These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

354 related items for PubMed ID: 17126869

  • 1. A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120.
    Beddows S, Franti M, Dey AK, Kirschner M, Iyer SP, Fisch DC, Ketas T, Yuste E, Desrosiers RC, Klasse PJ, Maddon PJ, Olson WC, Moore JP.
    Virology; 2007 Apr 10; 360(2):329-40. PubMed ID: 17126869
    [Abstract] [Full Text] [Related]

  • 2. Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1.
    Beddows S, Schülke N, Kirschner M, Barnes K, Franti M, Michael E, Ketas T, Sanders RW, Maddon PJ, Olson WC, Moore JP.
    J Virol; 2005 Jul 10; 79(14):8812-27. PubMed ID: 15994775
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The first hypervariable region of the gp120 Env glycoprotein defines the neutralizing susceptibility of heterologous human immunodeficiency virus type 1 isolates to neutralizing antibodies elicited by the SF162gp140 immunogen.
    Ching LK, Vlachogiannis G, Bosch KA, Stamatatos L.
    J Virol; 2008 Jan 10; 82(2):949-56. PubMed ID: 18003732
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. HIV-1 Envgp140 trimers elicit neutralizing antibodies without efficient induction of conformational antibodies.
    Bower JF, Li Y, Wyatt R, Ross TM.
    Vaccine; 2006 Jun 29; 24(26):5442-51. PubMed ID: 16621193
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140.
    Earl PL, Sugiura W, Montefiori DC, Broder CC, Lee SA, Wild C, Lifson J, Moss B.
    J Virol; 2001 Jan 29; 75(2):645-53. PubMed ID: 11134278
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1.
    Sanders RW, Vesanen M, Schuelke N, Master A, Schiffner L, Kalyanaraman R, Paluch M, Berkhout B, Maddon PJ, Olson WC, Lu M, Moore JP.
    J Virol; 2002 Sep 29; 76(17):8875-89. PubMed ID: 12163607
    [Abstract] [Full Text] [Related]

  • 14. Elicitation of neutralizing antibodies with DNA vaccines expressing soluble stabilized human immunodeficiency virus type 1 envelope glycoprotein trimers conjugated to C3d.
    Bower JF, Yang X, Sodroski J, Ross TM.
    J Virol; 2004 May 29; 78(9):4710-9. PubMed ID: 15078953
    [Abstract] [Full Text] [Related]

  • 15. Humoral response to oligomeric human immunodeficiency virus type 1 envelope protein.
    Richardson TM, Stryjewski BL, Broder CC, Hoxie JA, Mascola JR, Earl PL, Doms RW.
    J Virol; 1996 Feb 29; 70(2):753-62. PubMed ID: 8551612
    [Abstract] [Full Text] [Related]

  • 16. Analysis of the neutralizing antibody response elicited in rabbits by repeated inoculation with trimeric HIV-1 envelope glycoproteins.
    Grundner C, Li Y, Louder M, Mascola J, Yang X, Sodroski J, Wyatt R.
    Virology; 2005 Jan 05; 331(1):33-46. PubMed ID: 15582651
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
    Patil S, Kumar R, Deshpande S, Samal S, Shrivastava T, Boliar S, Bansal M, Chaudhary NK, Srikrishnan AK, Murugavel KG, Solomon S, Simek M, Koff WC, Goyal R, Chakrabarti BK, Bhattacharya J.
    J Virol; 2016 Jan 13; 90(7):3446-57. PubMed ID: 26763999
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.